1
Henrik Egesborg Hansen, Henrik Ege, Thomas Munk Plum: Method and apparatus for in vivo determination of the concentration in a body fluid of metabolically significant substances. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, October 28, 1997: US05680858 (401 worldwide citation)

A method for in vivo determination of the concentration in a body fluid of metabolically significant substance comprises storing of a needle with a sensor in a liquid-filled ampoule, brief insertion of the needle into a patient, recording of the output signal from the sensor, withdrawal of the needl ...


2
Steffen Hansen, Peter Christian Klitgaard: Dose display for an injection syringe. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, September 7, 1999: US05947934 (152 worldwide citation)

The present invention relates to injection syringes comprising a housing accommodating an ampoule containing medicine sufficient for a number of dosed injections. The syringe has a dose setting mechanism by which doses may be set by rotating a dose setting element relative to the housing and the dos ...


3
Martin Schulein, Kirsten B o slashed egh Levring: Methods for reducing the harshness of a cotton-containing fabric. Novo Nordisk, Steve T Zelzon Esq, Elias J Lambiris Esq, July 15, 1997: US05648263 (142 worldwide citation)

The present invention relates to methods of reducing the rate at which a cotton-containing fabric becomes harsh or of reducing the harshness of a cotton-containing fabric, comprising treating the cotton-containing fabric with a cellulase preparation obtained from a fungus, wherein the cellulase prep ...


4
Liselotte Bjerre Knudsen, Per Olaf Huusfeldt, Per Franklin Nielsen, Niels C Kaarsholm, Helle Birk Olsen, Søren Erik Bjørn, Freddy Zimmerdahl Pedersen, Kjeld Madsen: Derivatives of GLP-1 analogs. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, July 31, 2001: US06268343 (103 worldwide citation)

The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.


5
Helle Fabricius Woldike, Fred Hagen, Carsten Mailand Hjort, Sven Hastrup: Enzyme capable of degrading cellulose or hemicellulose. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, June 9, 1998: US05763254 (69 worldwide citation)

The present invention relates to isolated and purified cellulose- or hemicellulose-degrading enzymes, comprising a catalytically active domain, a carbohydrate binding domain and a linking B region which operably links the catalytically active domain and the carbohydrate binding domain, wherein the c ...


6
Peter Faarup, Palle Jakobsen, Anker Steen J o slashed rgensen, Henrik Klitgaard: Heterocyclic compounds and their preparation and use. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, July 8, 1997: US05646146 (66 worldwide citation)

The present invention relates to 9H-indeno[1,2-b]pyrazin-3(4H)-ones and 9H-indeno[1,2-b]pyrazine-2,3(1H,4H)-diones or tautomeric forms thereof which are useful in treating neurological and psychiatric diseases based on the antagonism of the glycine binding site on the NMDA receptor complex.


7
Steen Jensen, Philip Hansen: Method for producing powder formulation comprising an insulin. Novo Nordisk, Steven T Zelson Esq, Elias J Lambiris Esq, March 28, 2000: US06043214 (66 worldwide citation)

The present invention relates to a process for producing a therapeutic powder formulation, comprising (a) providing an acidic aqueous solution comprising an insulin or analoguc or derivative thereof and an enhancer; (b) adjusting the pH to a pH in the range of 4.5 to 7.4; (c) precipitating a product ...


8
Helle Fabricius Woldike, Fred Hagen, Carsten Mailand Hjort, Sven Hastrup: Enzyme capable of degrading cellulose or hemicellulose. Novo Nordisk, Steve T Zelson Esq, Elias J Lambiris Esq, November 11, 1997: US05686593 (62 worldwide citation)

The present invention relates to cellulose- or hemicellulose-degrading enzymes which is derivable from a fungus other than Trichoderma or Phanerochaete, and which comprises a carbohydrate binding domain homologous to a terminal A region of Trichoderma reesei cellulases, which carbohydrate binding do ...


9
Lars Thim, Birgitte Schjellerup Wulff, Martin Edward Judge, Ole Dragsbaek Madsen, Jens Juul Holst: Use of a pharmaceutical composition comprising an appetite-suppressing peptide. Novo Nordisk Als, Steve T Zelson Esq, Elias J Lambiris Esq, June 15, 1999: US05912229 (52 worldwide citation)

The present invention relates to appetite-suppressing peptides or an appetite-suppressing peptide-containing fraction for the treatment of obesity or type II diabetes.


10
Martin Schulein, Helle Outtrup, Per Lina Jorgensen, Mads Eskelund Bjornvad: Xyloglucan-specific alkaline xyloglucanase from bacillus. Novozymes, Elias J Lambiris Esq, Jason I Garbell Esq, July 31, 2001: US06268197 (50 worldwide citation)

A xyloglucanase having a relative xyloglucanase activity of at least 50% at pH 7 and either no or an insignificant cellulolytic activity is obtainable e.g. from a strain of Bacillus. A xyloglucanase comprising an amino acid sequence as shown in positions 30-261 of SEQ ID NO:2 or homologues may be de ...